Dr. Anna Farago, oncologist form the Massachusetts General Hospital, will explain in an oral presentation what kind of molecule lurbinectedin is, how it works, and what results were obtained from the phase I/II clinical study in combination with doxorubicin for the treatment of small-cell lung cancer, that led to the of the pivotal phase III ATLANTIS study, which is nearing completion. Dr. Farago is the lead investigator of this clinical trial. The presentation will take place on Wednesday the 21st of February at 11:50 a.m. (PT).
Lurbinectedin is currently under clinical investigation for different types of solid tumors such as small-cell lung cancer. When combined with doxorubicin, lurbinectedin reached a progression free survival of 5.3 months which compares favorably with historical data of topotecan as a single agent (the PFS varies between 3.1 and 3.5 months), This PFS increases up to 6.2 months in platinum sensitive patients. The data has shown so far that lurbinectedin does not produce mucositis, neuropathy or alopecia.
“In such a difficult disease setting with so few therapeutic options, lurbinectedin has shown encouraging data so far in terms of efficacy and tolerability. As the ATLANTIS phase III nears enrollment completion around mid-year, there is growing
Article originally posted at